Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 12/20 | 0.42 |
| ▸ | BDKRB2 | P30411 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701175 | 0.96 | KMT2A (0.43) | BDKRB1BDKRB2KMT2AMEN1F2 | |
| SCHEMBL699109 | 0.89 | BDKRB1 (0.48) | BDKRB1BDKRB2KMT2AMEN1 | |
| SCHEMBL700245 | 0.87 | BDKRB1 (0.49) | BDKRB1BDKRB2KMT2AMEN1 | |
| SCHEMBL3441548 | 0.79 | MEN1 (0.42) | BDKRB1BDKRB2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3441474 | 0.78 | BDKRB1 (0.47) | BDKRB1BDKRB2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3442054 | 0.78 | BDKRB1 (0.42) | BDKRB1BDKRB2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3441593 | 0.78 | BDKRB1 (0.48) | BDKRB1BDKRB2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3441695 | 0.78 | BDKRB1 (0.48) | BDKRB1BDKRB2KMT2AMEN1 | |
| SCHEMBL3311108 | 0.78 | BDKRB1 (0.47) | BDKRB1BDKRB2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3442419 | 0.78 | BDKRB1 (0.49) | BDKRB1BDKRB2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | claimed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | claimed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | BDKRB1 11/4885BDKRB2 9/4885KMT2A 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.